After ovarian cancer flop, PharmaMar's lurbinectedin makes the cut in small cell lung cancer
More than a year after its experimental drug, lurbinectedin, failed a late-stage test in platinum-resistant ovarian cancer patients, Spanish biotech PharmaMar on Monday said the agent met the main goal in patients with relapsed small cell lung cancer (SCLC) in a Phase II study.
The primary endpoint of the 105-patient trial was to measure the overall response rate, while secondary goals included progression-free survival and overall survival. Detailed study data will be provided at a future medical meeting, the company said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.